Advances in gene therapy for hemophilia

• DOI: 10.1007/s12038-020-00057-y
• Publication Date: 2020-07-02T06:49:30Z
• Authors: Olivia A Robles-R...; José J Pérez-Truj...; Arnulfo Villanuev...; Laura Villarreal-...; Luis J Marfil-Rivera; Humberto Rodrígue...; Aracely García-Ga...; Odila Saucedo-Cár...; María J Loera-Arias; Roberto Montes de...
• Keywords: 0301 basic medicine; 03 medical and health sciences; Genetic Vectors; Quality of Life; Humans; Hemorrhage; Genetic Therapy; Hemophilia A; 3. Good health

Hemophilia is a hereditary disorder that can be life-threatening in individuals who have severe spontaneous bleeding resulting from minor trauma or surgery. Although replacement therapy of the missing exogenous factor has improved patients' quality of life, it has not been possible to establish a long-term treatment. Due to the severity of the disease and the need for repetitive doses throughout the patient's life, replacement therapy has become a high-cost treatment option; therefore, the development of self-sustainable long-term therapies is critical. Hemophilia is a good candidate for gene therapy because it is a monogenic disease that can be counteracted by expression of the missing factor. In this article, we review some of the most relevant advances in gene therapy for this illness.